Register for our free email digests:
Latest From Barr Laboratories Inc.
Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.
California Supreme Court finds patents are ‘probablistic rather than ironclad,’ and outlines four-prong antitrust test that further complicates brand/generic deal making.
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.
- Implantable Devices
- Therapeutic Areas
- Respiratory, Pulmonary
- Harvard Apparatus Regenerative Technology Inc.
- North America
- Parent & Subsidiaries
- Biostage Inc.
- Senior Management
James McGorry, CEO
Thomas McNaughton, CFO
Saverio La Francesca, MD, EVP, CMO
- Contact Info
Phone: (774) 233-7300
84 October Hill Rd.
Holliston, MA 01746
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.